C

Chicago Research Center, Inc. | Chicago, IL

Research site

(Unclaimed)

Location

3401 N. Central Avenue, Chicago, Illinois, United States of America

Site insights

Top conditions

Top treatments

Aticaprant

AD109

JNJ-42847922

Armodafinil

Azetukalner

AD504

Resmetirom

Pregabalin

ONO-5129

Seltorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 47 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Active, not recruiting

Non-Alcoholic Fatty Liver Disease

Drug: Resmetirom

A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects

The study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compar...

Enrolling

Hypertension

Elevated Blood Pressure

Device: Zona Plus Device

Other: Relaxing Music App

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA2)

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling

Major Depressive Disorder

Drug: Placebo

Drug: Azetukalner

An Open-Label Study of Azetukalner in Major Depressive Disorder (X-NOVA-OLE)

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Invitation-only

Major Depressive Disorder

Drug: Azetukalner

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine